Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Merck & Co. Inc.

Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC

Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.

Clinical Trials ImmunoOncology

Risk-Based Approach To Protecting Data Integrity Outlined In Forthcoming PDA Report

An upcoming PDA technical report is expected to build on the concepts of an earlier report on laboratory systems and propose a risk-based approach for protecting data integrity using a nine-box grid for assessing data integrity risks.

Manufacturing Quality

AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
Sales & Earnings Companies

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?

BioPharmaceutical Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register